Foshan Amprozyme Biopharmaceutical

Foshan Amprozyme Biopharmaceutical is a Chinese biotechnology company specializing in the development and industrialization of large-molecule biologics, including biosimilars and innovative monoclonal antibodies. Founded in 2010 by a team with extensive experience in the U.S. biopharmaceutical industry, the company focuses on therapeutic areas such as oncology, hematology, and bone diseases. Its lead program, APZ001, is a biosimilar of cetuximab (Erbitux) for colorectal cancer that has reached Phase 3 clinical trials. Amprozyme operates advanced R&D laboratories and GMP-compliant pilot production facilities in Foshan and is expanding its manufacturing capabilities with a new headquarters and industrialization base in Guangzhou.